Background/Objectives: Cannabis use has a particularly high prevalence in individuals with psychotic disorders. Although cannabis use is generally associated with cognitive impairments in the general population, its impact on cognition in psychosis remains controversial. This study aimed to investigate the association between cannabis use and cognitive performance in a cohort of individuals affected by psychotic disorders. Methods: A total of 105 inpatients with psychotic disorders (mean age: 40.3 years; 34 females) were recruited from the University Hospital Center “Mother Teresa” in Tirana. Data collection included socio-demographic and clinical variables. Cognitive functioning was evaluated using the Montreal Cognitive Assessment (MoCA), while psychopathology was assessed with the Brief Negative Symptom Scale (BNSS), the Calgary Depression Scale for Schizophrenia (CDSS), the Psychotic Symptom Rating Scales (PSYRATS), and the Scale for the Assessment of Thought, Language, and Communication (TLC). Results: Cannabis users (CU) were more frequently male, younger, and exhibited an earlier onset of psychosis compared to non-users (No-CU). Importantly, CU demonstrated higher MoCA scores, with the most favorable outcomes observed among daily users. Conclusions: Contrary to the prevailing assumption that cannabis use exacerbates cognitive decline, our findings indicate an unexpected association between cannabis use and preserved cognitive functioning in psychosis. These results underscore the need to consider dosage, frequency, and cannabinoid composition (THC/CBD ratio) when interpreting cannabis-related cognitive outcomes in psychotic disorders.

To evaluate the psychometric properties and clinical utility of the THINC-it digital cognitive screening battery in depressive and mood disorders. Systematic review conducted in accordance with PRISMA 2020 and organized within a COSMIN-informed framework. PsycInfo, PubMed, Scopus, Web of Science, and Europe PMC were searched from inception to September 1, 2025, without language restrictions. Two independent reviewers screened records and extracted data on validity, reliability, measurement error, responsiveness, diagnostic test accuracy, and feasibility. Of 284 records identified, 17 studies were included. Construct validity was the most consistently supported measurement property: convergence was most consistent between Codebreaker and the Digit Symbol Substitution Test and between Trails and Part B of the Trail Making Test, and more variable for other pairings. Cutoffs with sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) were rarely reported. Test-retest reliability was reported in three studies, only one of which assessed patients rather than healthy controls; the standard error of measurement (SEM), minimal detectable change (MDC), and minimal clinically important difference (MCID) were never reported. Heterogeneity across populations, language versions, devices, and administration settings limited comparability and interpretation of longitudinal change. THINC-it is a brief digitalized cognitive screening battery (≈10-15 min) with potential utility for continuous, non-cutoff assessment. The current evidence provides the strongest support for its construct validity. Further studies are required to rigorously quantify measurement error, define the minimal clinically important difference (MCID), establish diagnostic accuracy, and evaluate equivalence across devices, settings, and language versions.